Exendin-4: A Long-Lasting GLP-1 Drug That Could Protect the Brain Against Alzheimer's and Parkinson's | Research

The takeaway

Exendin-4, a GLP-1 receptor agonist with extended half-life, shows neuroprotective potential against both Alzheimer's and Parkinson's disease through anti-inflammatory, anti-oxidative, and neurotrophic mechanisms.

Dual neurodegenerative potential
Exendin-4 shows neuroprotective effects in both Alzheimer's and Parkinson's disease preclinical models

What the researchers found

Exendin-4 demonstrates neuroprotective effects against both Alzheimer's and Parkinson's disease in preclinical models, operating through anti-inflammatory, anti-oxidative, and neurotrophic mechanisms.

Why it matters

Neither Alzheimer's nor Parkinson's has a disease-modifying treatment. Exendin-4 is already FDA-approved for diabetes, has a known safety profile, and shows brain-protective effects — making it a high-priority candidate for drug repurposing in neurodegenerative diseases.

The numbers in context

Exendin-4 affects multiple neuroprotective pathways; millions affected worldwide by neurodegenerative disorders.

How the study worked

Comprehensive narrative review synthesizing preclinical and clinical evidence for exendin-4's neuroprotective properties in Alzheimer's and Parkinson's disease models.

Who was studied

Review of preclinical and clinical neuroprotection evidence for exendin-4

What this study cannot tell us

Primarily preclinical evidence — human trial data is limited. Blood-brain barrier penetration of exendin-4 may limit its central nervous system effects. Optimal dosing for neuroprotection unknown. Multiple neurodegenerative disease mechanisms may not all be addressed by a single drug. Overlap with the GLP-1/Parkinson's review space.

How to read the evidence

Moderate evidence — extensive preclinical support across multiple disease models, with limited but encouraging clinical data. Definitive human trials needed.

When this study was published

Published in 2024. Captures the growing interest in GLP-1 agonist repurposing for neurodegenerative diseases.

The bigger picture

The search for neurodegenerative disease treatments has been marked by repeated clinical trial failures. Repurposing metabolic drugs like exendin-4 — which are already proven safe and target shared pathways between metabolic and neurodegenerative diseases — represents a pragmatic approach that could bypass years of safety testing.

Questions still open

Does exendin-4 have advantages over newer GLP-1RAs (like semaglutide) for brain penetration?
Can exendin-4 prevent or only slow neurodegenerative disease progression?
Should clinical trials test exendin-4 in early-stage AD/PD patients before significant neuronal loss?

Common questions

How could a diabetes drug help with Alzheimer's and Parkinson's?

Exendin-4 activates GLP-1 receptors in the brain, which reduces inflammation, protects nerve cells from damage, and promotes their survival. Both Alzheimer's and Parkinson's involve nerve cell death driven by inflammation and oxidative stress — exactly the problems exendin-4 appears to counteract in lab studies.

What makes exendin-4 special compared to other GLP-1 drugs?

Exendin-4 (marketed as exenatide) was the first GLP-1 drug approved and comes from Gila monster venom. It has been used for diabetes for nearly two decades, so its safety is well-established. It also has one of the longest research histories for brain effects, with clinical trials in Parkinson's patients already underway.

Read the original research

Exendin-4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease.

Chemical biology & drug design, 103(1), e14426

View on PubMed ↗Publisher’s paper ↗

Citation

Verma, Aanchal; Chaudhary, Shobhit; Solanki, Kunal; Goyal, Ahsas; Yadav, Harlokesh Narayan. (2024). Exendin-4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease.. Chemical biology & drug design, 103(1), e14426. https://doi.org/10.1111/cbdd.14426